Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 9,360 matching trials from the live ClinicalTrials.gov search.
Filters: Portland, Oregon Clear all
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 31, 2026, 7:51 AM EDT
Terminated Phase 3 Interventional Results available

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319
View directory record Official record
Conditions
Steroid-Refractory Acute Graft Versus Host Disease
Interventions
T-Guard
Drug
Lead sponsor
Xenikos
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

NCT04173507
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Avelumab, Talazoparib, Talazoparib Tosylate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
325
States / cities
Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 31, 2026, 7:51 AM EDT
Terminated Phase 2 Interventional

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

NCT00510471
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine
Drug
Lead sponsor
Genitope Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2008 · Synced Oct 31, 2026, 7:51 AM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 3 Interventional

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of XP12B in Women With Menorrhagia

NCT00401193
View directory record Official record
Conditions
Menorrhagia, Heavy Menstrual Bleeding
Interventions
Tranexamic acid tablets, Placebo tablets
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 31, 2026, 7:51 AM EDT
Terminated Phase 2 Interventional

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

NCT02793778
View directory record Official record
Conditions
Crohn's Disease
Interventions
CROWN, CROWN Placebo
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Dothan, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 31, 2026, 7:51 AM EDT
Not listed Phase 2 Interventional

Prehospital Kcentra for Hemorrhagic Shock

NCT04019015
View directory record Official record
Conditions
Trauma Injury
Interventions
Prothrombin Complex Concentrate, Human, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BMS-986158 in Subjects With Select Advanced Cancers

NCT02419417
View directory record Official record
Conditions
Advanced Tumors
Interventions
BMS-986158, Nivolumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 31, 2026, 7:51 AM EDT
Recruiting Phase 1 Interventional

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

NCT07814248
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions
TS-104
Drug
Lead sponsor
TwoStep Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Maumee, Ohio • Portland, Oregon • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

NCT00087555
View directory record Official record
Conditions
Fibromyalgia
Interventions
Xyrem (sodium oxybate) oral solution, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
20
States / cities
Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 31, 2026, 7:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining Bladder Control Using Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI)

NCT01110278
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 31, 2026, 7:51 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation of Suicide Risk Models in Health Systems

NCT06060535
View directory record Official record
Conditions
Suicide, Attempted, Suicide, Fatal
Interventions
Suicide Attempt Risk Model Care Pathway
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
394,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Bloomington, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 7:51 AM EDT
Recruiting Phase 2 Interventional

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

NCT06806033
View directory record Official record
Conditions
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Interventions
Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
33
States / cities
Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Not applicable Interventional Results available

Community Central Line Infection Prevention Trial

NCT02351258
View directory record Official record
Conditions
Infection
Interventions
70% Isopropyl alcohol embedded caps, Usual Care
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Day to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, placebo, ranibizumab intravitreal injection
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 31, 2026, 7:51 AM EDT
Active, not recruiting Not applicable Interventional

Venous Sinus Stenting With the River Stent in IIH

NCT03556085
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous sinus stenting (Serenity River)
Device
Lead sponsor
Serenity Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Buffalo, New York • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL, placebo-metreleptin 1 mL, Pramlintide acetate 180 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 2 Interventional

S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00004217
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, valspodar
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
89
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Not applicable Interventional Results available

Neurosciences-Intensive Care Unit Electrical Stimulation

NCT03547687
View directory record Official record
Conditions
Intensive Care (ICU) Myopathy
Interventions
Electrical Stimulation Treatment, Neuromuscular Electrical Stimulation Treatment
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 31, 2026, 7:51 AM EDT
Completed Phase 4 Interventional

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

NCT00337493
View directory record Official record
Conditions
Kidney Transplantation
Interventions
mycophenolate mofetil [CellCept], Cyclosporine or tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 31, 2026, 7:51 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

NCT07871214
View directory record Official record
Conditions
Early-Stage Non-Small Cell Lung Cancer
Interventions
Pumitamig, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 7:51 AM EDT